• Testing Australia: 4,400 MetaXplore tests sold, up 146% vs PCP
• Australia MetaPanel: 420 tests sold, up 171% vs H2 FY24
• UK Invivo Clinical: Transitioning to new growth phase with MetaXplore

Microba Life Sciences Limited (ASX: MAP) reported its results for the six-month period ending 31 December 2024 ('H1 FY25'). The company saw continued strong growth for its MetaXplore test in Australia, with 4,400 tests sold, up 146% vs the prior corresponding period (PCP). The number of ordering clinician accounts also grew 92% vs PCP to over 735. In Australia, the company's MetaPanel clinical adoption continued to build, with 420 tests sold in H1 FY25, up 171% vs H2 FY24. Total MetaPanel sales since launch reached 575 tests as of December 31, 2024. In the UK, the company's Invivo Clinical business remains robust, delivering growth during the period, while the UK testing business is transitioning to a new growth phase following the first access to MetaXplore in the UK in October 2024. The initial UK clinician test referral rates were similar to Australia, demonstrating healthy initial traction and market acceptance, providing confidence to accelerate towards full UK market access in H2 FY25. Microba also made progress in its therapeutics programs, focused on advancing the Inflammatory Bowel Disease, Immuno-Oncology, and Autoimmune programs. The company reported H1 revenue of $8.08 million, up 147% vs PCP, and H1 cash receipts of $8.98 million, up 144% vs PCP. Microba had $17.3 million in cash and equivalents at 31 December 2024.

Microba remains intensively focused on executing its testing and therapeutic business strategies. The company is gaining strong clinical adoption of its diagnostic tests, exemplified by the break-out growth of MetaXplore sales in Australia, giving it conviction in the opportunity and growth profile ahead including plans for expansive UK growth and US entry with public reimbursement.